Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Current Value
$20.731 Year Return
Current Value
$20.731 Year Return
Market Cap
$1.50B
P/E Ratio
-153.88
1Y Stock Return
30.78%
1Y Revenue Growth
54.41%
Dividend Yield
0.00%
Price to Book
3.4
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EFSC | 47.33% | $2.18B | +54.22% | 1.76% |
KREF | 41.17% | $796.38M | -5.46% | 10.31% |
KFRC | 40.86% | $1.10B | -8.71% | 0.66% |
JBI | 40.23% | $1.00B | -31.76% | 0.00% |
AMWD | 37.93% | $1.46B | +29.41% | 0.00% |
NVEC | 37.81% | $364.49M | +7.38% | 5.30% |
MBIN | 37.75% | $1.78B | +16.49% | 0.90% |
NTLA | 37.29% | $1.44B | -50.35% | 0.00% |
FATE | 37.18% | $248.29M | -11.02% | 0.00% |
NECB | 37.17% | $415.57M | +76.37% | 1.37% |
TRST | 36.82% | $691.41M | +34.26% | 3.98% |
CSV | 36.62% | $590.66M | +75.49% | 1.16% |
BEAM | 36.06% | $2.09B | -9.52% | 0.00% |
XHR | 35.83% | $1.51B | +19.71% | 3.13% |
TMDX | 35.54% | $2.78B | +22.14% | 0.00% |
CLFD | 35.10% | $398.66M | +4.48% | 0.00% |
ATRO | 34.98% | $575.48M | +5.29% | 0.00% |
ALLO | 34.90% | $444.50M | -24.82% | 0.00% |
MATW | 34.84% | $731.28M | -31.68% | 4.06% |
TIPT | 34.61% | $801.52M | +19.70% | 1.11% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OBDE | 0.02% | $1.82B | -2.27% | 4.76% |
ALL | -0.04% | $52.06B | +45.67% | 1.85% |
TRVG | 0.05% | $37.05M | -37.92% | 0.00% |
PGR | 0.06% | $149.10B | +57.29% | 0.45% |
MSDL | 0.11% | $1.83B | +0.66% | 7.26% |
HUSA | -0.12% | $16.69M | -11.56% | 0.00% |
MAGN | 0.14% | $638.97M | -3.42% | 0.00% |
NEUE | -0.15% | $40.93M | -34.13% | 0.00% |
DMLP | 0.19% | $1.58B | +18.00% | 10.54% |
SOHU | -0.27% | $406.50M | +43.52% | 0.00% |
CHD | -0.39% | $27.18B | +19.50% | 1.03% |
CL | 0.42% | $76.48B | +22.25% | 2.12% |
BSM | 0.44% | $3.17B | -13.01% | 10.65% |
COCO | -0.48% | $2.01B | +24.49% | 0.00% |
RLX | 0.63% | $1.69B | -17.76% | 0.00% |
LITB | -0.64% | $35.48M | -75.45% | 0.00% |
SAVA | 0.67% | $1.35B | +25.50% | 0.00% |
HIHO | -0.68% | $8.63M | 0.00% | 6.12% |
FCN | 0.68% | $7.10B | -10.74% | 0.00% |
CLLS | 0.73% | $141.30M | -30.99% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -16.59% | $21.46B | +15.84% | 1.11% |
WM | -15.60% | $87.92B | +27.58% | 1.34% |
PRPO | -14.69% | $9.10M | -13.65% | 0.00% |
CME | -14.63% | $82.76B | +9.21% | 1.98% |
GAN | -13.83% | $83.39M | +21.19% | 0.00% |
RSG | -13.42% | $66.05B | +31.79% | 1.04% |
UPS | -11.13% | $113.67B | -11.06% | 4.89% |
KMB | -10.66% | $45.22B | +11.57% | 3.58% |
ASPS | -9.06% | $22.36M | -80.26% | 0.00% |
ZTO | -7.13% | $12.58B | -4.71% | 4.73% |
UUU | -7.07% | $4.97M | -41.89% | 0.00% |
K | -6.89% | $27.77B | +52.50% | 2.79% |
STG | -6.66% | $35.67M | +7.92% | 0.00% |
WELL | -6.46% | $86.04B | +55.71% | 1.86% |
T | -6.41% | $163.09B | +40.40% | 4.87% |
PCAR | -6.02% | $57.87B | +24.80% | 1.06% |
MCK | -5.80% | $78.15B | +35.51% | 0.42% |
MAT | -5.71% | $6.17B | +0.66% | 0.00% |
MNOV | -5.44% | $93.19M | +2.15% | 0.00% |
NAPA | -5.36% | $1.63B | +9.61% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWC | 44.13% | $933.99M | 0.6% |
PSC | 41.44% | $702.17M | 0.38% |
XBI | 41.38% | $6.58B | 0.35% |
SFYX | 41.32% | $105.21M | 0.06% |
IWM | 40.51% | $75.73B | 0.19% |
VTWO | 40.48% | $12.38B | 0.1% |
IJT | 40.41% | $6.64B | 0.18% |
SLYG | 40.35% | $3.69B | 0.15% |
GSSC | 40.21% | $529.86M | 0.2% |
IWO | 40.08% | $12.56B | 0.24% |
ARKG | 39.93% | $1.13B | 0.75% |
FYX | 39.55% | $959.00M | 0.6% |
PBE | 39.28% | $258.53M | 0.58% |
PRFZ | 39.28% | $2.65B | 0.39% |
IWN | 39.22% | $13.17B | 0.24% |
VBK | 39.13% | $19.31B | 0.07% |
BSVO | 38.88% | $1.53B | 0.47% |
CALF | 38.88% | $8.93B | 0.59% |
XSMO | 38.81% | $1.25B | 0.39% |
SPSM | 38.63% | $12.72B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XHLF | 0.20% | $874.27M | 0.03% |
DBMF | -0.39% | $1.02B | 0.85% |
UNG | 0.50% | $908.80M | 1.06% |
BOXX | 0.61% | $4.43B | 0.1949% |
IVOL | 0.70% | $548.70M | 1.02% |
FLRN | -0.77% | $2.33B | 0.15% |
SOYB | -0.79% | $27.32M | 0.22% |
CCOR | 0.84% | $109.04M | 1.18% |
GBIL | -0.90% | $5.60B | 0.12% |
DUSB | -0.97% | $797.63M | 0.15% |
SGOV | -1.02% | $27.53B | 0.09% |
CLOI | -1.56% | $715.40M | 0.4% |
DBO | 2.29% | $217.57M | 0.77% |
XBIL | -2.36% | $637.70M | 0.15% |
KRBN | -2.46% | $242.47M | 0.85% |
DBA | -2.49% | $755.88M | 0.93% |
ULST | 2.59% | $535.47M | 0.2% |
DBE | 3.14% | $50.13M | 0.77% |
CSHI | 3.25% | $482.85M | 0.38% |
JUCY | -3.28% | $324.29M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -23.15% | $388.04M | 1.43% |
VIXY | -21.50% | $195.31M | 0.85% |
WEAT | -15.24% | $120.27M | 0.28% |
TAIL | -11.46% | $67.98M | 0.59% |
BSCO | -8.71% | $2.35B | 0.1% |
CTA | -8.44% | $350.27M | 0.78% |
AGZD | -8.29% | $142.76M | 0.23% |
UUP | -8.00% | $309.25M | 0.77% |
CORN | -7.91% | $61.12M | 0.2% |
MINT | -7.69% | $11.62B | 0.35% |
USDU | -7.10% | $201.97M | 0.5% |
KMLM | -6.50% | $353.87M | 0.9% |
EQLS | -6.38% | $76.08M | 1% |
HDRO | -5.93% | $164.26M | 0.3% |
KCCA | -5.19% | $220.51M | 0.87% |
TBIL | -3.76% | $4.38B | 0.15% |
JUCY | -3.28% | $324.29M | 0.6% |
DBA | -2.49% | $755.88M | 0.93% |
KRBN | -2.46% | $242.47M | 0.85% |
XBIL | -2.36% | $637.70M | 0.15% |
Yahoo
We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer […]
Yahoo
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’
Yahoo
It's been a mediocre week for Kiniksa Pharmaceuticals International, plc ( NASDAQ:KNSA ) shareholders, with the stock...
Yahoo
Kiniksa Pharmaceuticals International ( NASDAQ:KNSA ) Third Quarter 2024 Results Key Financial Results Revenue...
Yahoo
Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call
Yahoo
Kiniksa Pharmaceuticals International PLC (KNSA) reports a 73% year-over-year revenue increase, raises full-year sales guidance, and continues to expand its prescriber base.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.